as 12-05-2024 1:41pm EST
With roughly one third of the global branded diabetes treatment market, Novo Nordisk is the leading provider of diabetes-care products in the world. Based in Denmark, the company manufactures and markets a variety of human and modern insulins, injectable diabetes treatments such as GLP-1 therapy, oral antidiabetic agents, and obesity treatments. Novo also has a biopharmaceutical segment (constituting roughly 10% of revenue) that specializes in protein therapies for hemophilia and other disorders.
Founded: | 1923 | Country: | Denmark |
Employees: | N/A | City: | N/A |
Market Cap: | 530.0B | IPO Year: | N/A |
Target Price: | $144.20 | AVG Volume (30 days): | 5.9M |
Analyst Decision: | Strong Buy | Number of Analysts: | 5 |
Dividend Yield: | Dividend Payout Frequency: | Semi-Annual | |
EPS: | 3.17 | EPS Growth: | 26.84 |
52 Week Low/High: | $94.73 - $148.15 | Next Earning Date: | 01-29-2025 |
Revenue: | $40,469,178,712 | Revenue Growth: | 26.15% |
Revenue Growth (this year): | 25.02% | Revenue Growth (next year): | 20.47% |
NVO Breaking Stock News: Dive into NVO Ticker-Specific Updates for Smart Investing
Investor's Business Daily
6 hours ago
Reuters
7 hours ago
Zacks
7 hours ago
Barrons.com
a day ago
MT Newswires
a day ago
Morningstar Research
a day ago
Clinical Trials Arena
a day ago
Yahoo Finance Video
a day ago
The information presented on this page, "NVO Novo Nordisk A/S - Stocks Price | History | Analysis", including historical data, forecasts, news, insider information, and predictions, is provided for educational purposes only. It should not be considered as financial advice or a recommendation to buy or sell any securities. Decisions regarding investments should be made only after careful consideration and consultation with a qualified financial advisor. We do not endorse or guarantee the accuracy or reliability of the information provided, and we disclaim any liability for financial losses incurred as a result of decisions made based on the information presented.